Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

Clinical and Experimental Rheumatology

Volumn 32, Issue 2, 2014, Pages 231-236

  Genre, Fernanda ^a   López Mejias, Raquel ^a   Miranda Filloy, José A ^b   Ubilla, Begoña ^a   Carnero López, Beatriz ^c   Gómez Acebo, Inés ^d   Blanco, Ricardo ^a   Ochoa, Rodrigo ^a   Arias Bajo, Mónica ^a   Rueda Gotor, Javier ^a   Paz Carreira, José ^b   González Juanatey, Carlos ^b   Llorca, Javier ^d   González Gay, Miguel A ^a  

^a Epidemiology Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division IFIMAV ^*  (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Ankylosing spondylitis; Anti TNF antibody infliximab; Atherosclerosis; Inflammation; Osteopontin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOPOIETIN 2; APELIN; C REACTIVE PROTEIN; GHRELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA B27 ANTIGEN; INFLIXIMAB; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; N(G),N(G) DIMETHYLARGININE; NAPROXEN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPONTIN; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; ATHEROSCLEROSIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NON DIABETIC ANKYLOSING SPONDILITIS; NON DIABETIC ANKYLOSING SPONDYLITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; SPAIN; TRIACYLGLYCEROL BLOOD LEVEL; DRUG RESPONSE; INFLAMMATION; MIDDLE AGED; OBESITY; PROTEIN DETERMINATION;

ADULT; ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; METABOLISM; MIDDLE AGED; OSTEOPONTIN; OUTPATIENTS; RISK FACTORS; SPAIN; SPONDYLITIS, ANKYLOSING; STATISTICS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902128301     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. AZEVEDO VF, PECOITS-FILHO R: Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int 2010; 30: 1411-6.
2. CAPKIN E, KIRIS A, KARKUCAK M et al.: Joint Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 2011; 78: 378-82.
3. GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MIRANDA-FILLOY JA et al.: The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88: 358-65.
4. CHOI ST, KIM JH, KANG EJ et al.: Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47: 1775-9.
5. BRIGGS TA: Osteopontin-a biomarker for organ damage in paediatric lupus?. Arthritis Res Ther 2013; 15: 110.
6. HAYLOCK DN, NILSSON SK: Osteopontin: a bridge between bone and blood. Br J Haematol 2006; 134: 467-74.
7. GüRSOY G, ALAGöZ S, ACAR Y, DEMIRBAS B, çETINER H, KILIç Z: Osteopontin a new probable marker for atherosclerosis in obese women? Clin Rev Opin 2010; 2: 35-40.
8. OHMORI R, MOMIYAMA Y, TANIGUCHI H et al.: Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170: 333-7.
9. GOLLEDGE J, McCANN M, MANGAN S, LAM A, KARAN M: Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004; 35: 1636-41.
10. D'ANGELO S, PALAZZI C, CANTINI F et al.: Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues. Clin Exp Rheumatol 2011; 29: 865-70.
11. PALAZZI C, D'ANGELO S, CANTINI F et al.: Etanercept in spondyloarthropathies. Part I: current evidence of efficacy. Clin Exp Rheumatol 2011; 29: 858-64.
12. HELDMANN F, BRANDT J, van der HORSTBRUINSMA IE et al.: The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011; 29: 672-80.
13. MIRANDA-FILLOY JA, LLORCA J, CARNEROLÓPEZ B, GONZÁLEZ-JUANATEY C, BLANCO R, GONZÁLEZ-GAY MA: TNF-a antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012; 30: 850-5.
14. MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R, GENRE F et al.: Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-a antagonist therapy. Clin Exp Rheumatol 2013; 31: 365-71.
15. MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R, GENRE F et al.: Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-a antagonist therapy. Clin Exp Rheumatol 2013; 31: 538-45.
16. GENRE F, MIRANDA-FILLOY JA, LÓPEZMEJIAS R et al.: Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-a antagonist therapy. Clin Exp Rheumatol 2013; 31: 532-7.
17. GENRE F, LÓPEZ-MEJÍAS R, MIRANDA-FILLOY JA et al.: Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-a therapy. Clin Exp Rheumatol 2013 Aug 26 [Epub ahead of print].
18. GENRE F, LÓPEZ-MEJÍAS R, MIRANDA-FILLOY JA et al.: Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-a antagonist therapy. Clin Exp Rheumatol 2013; 31: 749-55.
19. GENRE F, MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R et al.: Antitumour necrosis factor-a therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients. Ann Rheum Dis 2013; 72: 1265-7.
20. van der LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
21. GONZALEZ-GAY MA, LLORCA J, GARCIAUNZUETA MT et al.: High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 596-603.
22. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C et al.: Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-6.
23. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM et al.: Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-9.
24. van der HEIJDE D, SIEPER J, MAKSYMOWYCH WP et al.: 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-8.
25. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
26. OHMORI R, MOMIYAMA Y, TANIGUCHI H et al.: Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003; 170: 333-7.
27. GOLLEDGE J, McCANN M, MANGAN S, LAM A, KARAN M: Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004; 35: 1636-41.
28. LUOMALA M, PäIVä H, THELEN K et al.: Osteopontin levels are associated with cholesterol synthesis markers in mildly hypercholesterolaemic patients. Acta Cardiol 2007; 62: 177-81.
29. STEITZ SA, SPEER MY, McKEE MD et al.: Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002; 161: 2035-46.
30. MATSUI Y, RITTLING SR, OKAMOTO H et al.: Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 1029-34.
31. ISODA K, KAMEZAWA Y, AYAORI M, KUSUHARA M, TADA N, OHSUZU F: Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 2003; 107: 679-81.
32. WESTRA J, de GROOT L, PLAXTON SL et al.: Angiopoietin-2 is highly correlated with inflammation and disease activity in recentonset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology (Oxford) 2011; 50: 665-73.
33. LOPEZ-MEJIAS R, CORRALES, GENRE F et al.: Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013; 31: 761-6.